Somavert for terminal hypertrophy can be prescribed at Big 5

Severance and other major medical institutions nationwide can prescribe it

SEN-3614 Study Demonstrates Validity IGF-I Concentration Reduction

Somavert, a new drug for terminal hypertrophy, can be prescribed at a general hospital.

 

According to related industries, Pfizer Korea's Somavert has currently passed DC of the Big 5 higher-level medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St.

 

Mary's Hospital, AMC, and Sinchon Severance Hospital.

 

Currently, it can be prescribed in most major hospitals nationwide.

 

Somavert has been listed on the insurance benefit list since September last year, making it easy to access patients.

 

Somavert demonstrated its validity through a SEN-3614 study, a 12-week randomized, double-blind core study in 12 patients with terminal hypertrophy.

 

112 patients were randomly assigned to the Pegvisomant daily administration group of 10 mg, 15 mg, and 20 mg and placebo administration group, respectively, and the primary validity evaluation variable in the study was a change in serum IGF-I concentration at 12 weeks compared to the baseline.

 

As a result of the study, the median serum IGF-I concentration at 12 weeks compared to the baseline was 4.0±16.8%, 26.7±27.9%, 50.1±26.7%, and 62.5±21.3%, respectively, in the placebo, 10 mg daily, 15 mg, and 20 mg administration groups.

 

The proportion of patients whose serum IFG-I concentration returned to normal to baseline in the placebo-administered group, the Pegvisomant daily 10 mg-administered group, the 15 mg-administered group, and the 20 mg-administered group were 10%, 54%, 81%, and 89%, respectively, indicating that Pegvisomant was significantly higher in all three doses compared to the placebo Somavert did not respond appropriately to surgery and radiation therapy, and was approved in Korea in September last year for the treatment of adult terminal hypertrophy patients with insulin-like growth factor-I (IGF-I) concentration or intolerance due to Somatostatin mitosis treatment.